Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial.
- Citation:
- Ann Oncol vol 33 (4) 384-94
- Year:
- 2022
- Type:
- Manuscript
- Funding:
- AFT
- Endpoint:
- Secondary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- ppub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- 11
- Parents:
- 3604
- Children:
- None
- Pharmas:
- AbbVie Inc.
- Grants:
- Corr. Author:
- Authors:
- C E Geyer W M Sikov J Huober H S Rugo N Wolmark J O'Shaughnessy D Maag M Untch M Golshan J Ponce Lorenzo O Metzger M Dunbar W F Symmans P Rastogi J H Sohn R Young G S Wright C Harkness K McIntyre D Yardley S Loibl
- Networks:
- Study
- AFT-04
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords:
- carboplatin, neoadjuvant chemotherapy, phase III, triple-negative breast cancer, veliparib